Product Description
Mechanisms of Action: FXa Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Takeda
Company Location: TOKYO M0 103-8668
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Acute Coronary Syndrome|Thrombosis|Venous Thromboembolism
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
TAK-442_202 | P2 |
Completed |
Acute Coronary Syndrome |
2010-06-01 |
|
2008-000091-24 | P2 |
Completed |
Acute Coronary Syndrome |
2009-06-26 |
|
TAK-442_201 | P2 |
Completed |
Venous Thromboembolism |
2008-10-01 |
|
JapicCTI-090865 | P2 |
Completed |
Thrombosis |
None |